Sanofi v Amgen antibody case lands front of queue at UPC
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.
Effects of GSK v Teva ripple after SCOTUS denies cert
Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.
South Africa: Hope for measures to prevent abuse of the patent system
Government-led schemes to incentivise patents are leading to delays and prejudice against legitimate applicants. Tyron Grant of Spoor and Fisher explains how South Africa is tackling the problem.
Plant variety rights: UK holders must act
An important post-Brexit deadline for UK holders of Retained EU Plant Variety Rights is approaching, explain Alice Smart and Simon Bradbury of Appleyard Lees.
Brazil: The patent combination conundrum
It may not be straightforward but it is possible to obtain protection for valuable combination patents in Brazil, say Lívia Figueiredo and Priscila Kashiwabara of Kasznar Leonardos Intellectual Property.
Why the UPC will be rewarding for US businesses
Pinsent Masons and Sterne, Kessler, Goldstein, & Fox consider why the Unified Patent Court, due to open on June 1, 2023, will make Europe a more attractive patent litigation venue for US businesses.
Amgen v Sanofi: Scotus grapples with enablement
As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Humira: lessons from 20 years of patents, pricing and profits
As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.
The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn
The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.
Pfizer’s pregabalin litigation: the latest twist
The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
